Mineralocorticoid excess and left ventricular hypertrophy
https://doi.org/10.18705/1607-419X-2008-14-3-211-218
Abstract
Primary aldosteronism is one of the most prevalent reasons of secondary hypertension. Mineralocorticoid excess is on independent powerful pathogenic factor of left ventricular hypertrophy and its diastolic dysfunction. The degree of participation of aldosterone precursors in left ventricular remodeling is unknown. Two case reports concerning the peculiarities of different mineralocorticoid influence on left ventricle structure and function are described in the paper.
About the Authors
A. V. Barsukov
Military medical academy
Russian Federation
Russian Federation
Z. V. Bagaeva
Military medical academy
Russian Federation
Russian Federation
D. V. Kadin
Military medical academy
Russian Federation
Russian Federation
V. Baranov
Military medical academy
Russian Federation
Russian Federation
S. Shustov
Military medical academy
Russian Federation
Russian Federation
References
1. Conn JW. Primary aldosteronism. In: Hypertension: Pathophysiology and treatment, 1 st ed. Anonymous, New York: McGraw-Hill; 1977: 768-780.
2.
3. Fraser R, Davies DL, Connell JMC. Hormones and hypertension. Clin Endocrinol 1989; 31 (6): 701-746.
4.
5. Rossi GP. Bernini G, Caliumi С et al. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300.
6.
7. Favia G, Lumachi F, Scarpa V, D'Amico DF. Adrenalectomy in primary aldosteronism: a long-term follow-up study in 52 patients. World J Surg 1992; 16 (4): 680-683.
8.
9. Nishimura M, Uzu T, Fujii Т et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-266.
10.
11. Rossi GP, Pessina AC, Heagerty AM. Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens 2008; 26:613-621.
12.
13. Stewart PM Mineralocorticoid hypertension. Lancet 1999; 353: 1341-1347.
14.
15. Hatakeyama H, Miyamori I, Fujita Т et al. Vascular aldosteron: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269:24316-24320.
16.
17. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-314.
18.
19. Gomez-Sanchez EP, Zhou M, Gomez-Sanchez CE. Mineralocorticoids, salt and high blood pressure. Steroids 1996; 61:181-184.
20.
21. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. New Engl J Med 2006; 351: 33-41.
22.
23. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependence. Circulation. 1991; 83: 13-25.
24.
25. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988; 62: 749-756.
26.
27. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583.
28.
29. Navarro-Lopez F, Coca A, Pare JC et al. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity. Eur Heart J 1993; 14 (Suppl J): 38-41.
30.
31. Schunkert H, Hense HW, Muscholl M et al. Associations between circulating components of the rennin-angiotensinaldosterone system and left ventricular mass. Heart 1997; 77: 24-31.
32.
33. Юренев АП, Devereux RB, Гончарова ЛН и др. Оценка функционального состояния миокарда у больных гипертонической болезнью и гиперальдостеронизмом. Кардиология 1997; 37 (9): 22-25.
34.
35. Космачена ЕД, Сергакова ЛМ, Атьков ОЮ и др. Влияние оперативного лечения на гипертрофию миокарда левого желудочка у больных с симптоматическими артериальными гипертониями. Кардиология 1991; 31 (4): 25-28.
36.
37. Сахнова ТА, Арабидзе ГГ, Гаджаева ФУ и др. Компьютерная векторкардиографическая оценка состояния левых отделов сердца у больных с первичным гиперальдостеронизмом. Кардиология 1995; 35 (8): 25-29.
38.
39. Rossi GP, Sacchetto A, Visentin P et al. Changes in Left Ventricular Anatomy and Function in Hypertension and Primary Aldosteronism. Hypertension 1996; 27 (5): 1039-1045.
40.
41. Matsumura K, Fujii K, Oniki H et al. Role of aldosterone left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19: 10-12.
42.
43. Denolle T, Hanon O, Mounier-Vehier С et al. What tests should be conducted for secondary arterial hypertension in hypertensive patients resistant to treatment? Arch Mal Coeur Vaiss 2000; 90: 1037-1039.
44.
45. Tanabe A, Naruse M, Naruse К et al. Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension. Hypertens Res 1997; 20 (2): 85-90.
46.
47. Shigematsu Y, Hamada M, Okayama H et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29 (3): 723-727.
48.
49. Шустов СБ, Баранов ВЛ, Кадин ДВ. Состояние сердечной мышцы у больных, прооперированных по поводу синдрома Кона. Вестник Военно-медицинской академии. 2000; (1): 40-44.
50.
51. Парфенова ЕВ, Дьяконова ЕГ, Масенко ВП и др. Содержание в крови гормонов, нсйромедиаторов и гипертрофия левого желудочка у больных гипертонической болезнью. Кардиология 1995; 35 (7): 18-23.
52.
53. Brilla CG, Zhou G, Weber KT. Aldosterone-mediated stimulation of collagen synthesis in cultured cardiac fibroblasts J Hypertens 1992; 10 (4): S7.
54.
55. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25 (5): 563-575
56.
57. Гиляревский CP, Орлов ВА, Гвинджилия ТВ, Ивасенко ЛА. Новые аспекты терапии антагонистом альдостерона спиронолактоном. Кардиология 1995; 35 (7): 53-56.
58.
59. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Circ Res. 1991; 69: 107-115
60.
61. Rossi GP, Sacchetto A, Pavan E el al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95: 1471-1478.
62.
63. Holaj R, Zelinka T, Wichterle D et al. Increased intimamedia thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451-1457.
64.
65. Sanderson JE, Cockram CS, Yu CM et al. Myocardial fibrosis and hyperaldosteronism [letter]. Eur Heart J 1996; 17 (11): 1761-1762.
66.
67. Calo L, Scognamiglio R, Nistri S et al. Evidence of myocardial dysfunction in Bartter's syndrome. Am J Nephrol 1997; 17(2): l24-127.
68.
69. Schmitz U, Ко Y, Becher H et al. Evidence for cardiovascular remodeling in a patient with Bartter's syndrome. Clin Investig. 1994; 72(11): 874-877.
70.
71. Шкроб ОС, Ветшев ПС, Кузнецов НС. Диагностика, хирургическое лечение и прогноз при эндокринных гипертониях надпочечникового генеза. Хирургия 1996; (3): 17-23.
72.
73. Weigel RJ, Wells SA, Gunnells JC, Leight GS. Surgical treatment of primary hyperaldosteronism. Ann Surg 1994; 219 (4): 347-352.
74.
75. Агаев РА. Первичный гиперальдостеронизм (клиника, диагностика, хирургическое лечение): Автореф. дис. д-ра мед. наук. - М., 1993. - 46 с.
76.
77. Шустов С.Б., Яковлев В.А., Баранов В.Л., Карлов В.А. Артериальные гипертензиии. - СПб.: Специальная литература, 1997. - 320 с.
78.
79. Giacchetti G, Ronconi V, Turchi F et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 2007; 25: 177-186.
80.
81. Арабидзс ГГ, Чихладзе НМ, Сергакова ЛМ, Яровая ЕБ. Структура и функция миокарда левого желудочка у пациентов с первичным гиперальдостеронизмом. Тер. Арх. 1999; 71 (9): 13-19.
82.
83. Pimenta E, Calhoun DA. Primary aldosteronism: diagnosis and treatment. J Clin Hypertens 2006; 8: 887-893.
84.
85. Barsukov A., Bagaeva Z., Kizishin V., Lokshina Т., Mukhortova V., Shoustov S. Concentric and excentric left ventricle hypertrophy in essential hypertension: Echocardiographic data. J Hypertens 2008; 26 (suppl. 1): S 414.
86.
Review
For citations:
Barsukov A.V., Bagaeva Z.V., Kadin D.V., Baranov V., Shustov S. Mineralocorticoid excess and left ventricular hypertrophy . "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2008;14(3):211-218. (In Russ.) https://doi.org/10.18705/1607-419X-2008-14-3-211-218
Views:
882
Email this article 